Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amparo Ruiz

Showing results (171-180 of 179) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 179 results.
International Journal of Cardiology|May 27, 2014
Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients and of an experimental model in swineVicente Bodi, Juan M Ruiz-Nodar, Eloisa Feliu, et al.
Breast Cancer Research and Treatment|October 1, 2011
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancerFrederik Marmé, Wiebke Werft, Anne Walter, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Breast Cancer Research and Treatment|February 21, 2013
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancerMiguel Martín, Aleix Prat, Alvaro Rodríguez-Lescure, et al.
The New England Journal of Medicine|December 3, 2010
Adjuvant docetaxel for high-risk, node-negative breast cancerMiguel Martín, Miguel A Seguí, Antonio Antón, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 studyMiguel Martín, Amparo Ruiz, Manuel Ruiz Borrego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2015
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 StudyMiguel Martín, Amparo Ruiz Simón, Manuel Ruiz Borrego, et al.
Journal of the National Cancer Institute|May 29, 2008
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancerMiguel Martín, Alvaro Rodríguez-Lescure, Amparo Ruiz, et al.
Pageof 18

Showing results (171-180 of 179) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 179 results.
International Journal of Cardiology|May 27, 2014
Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients and of an experimental model in swineVicente Bodi, Juan M Ruiz-Nodar, Eloisa Feliu, et al.
Breast Cancer Research and Treatment|October 1, 2011
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancerFrederik Marmé, Wiebke Werft, Anne Walter, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Breast Cancer Research and Treatment|February 21, 2013
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancerMiguel Martín, Aleix Prat, Alvaro Rodríguez-Lescure, et al.
The New England Journal of Medicine|December 3, 2010
Adjuvant docetaxel for high-risk, node-negative breast cancerMiguel Martín, Miguel A Seguí, Antonio Antón, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 studyMiguel Martín, Amparo Ruiz, Manuel Ruiz Borrego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2015
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 StudyMiguel Martín, Amparo Ruiz Simón, Manuel Ruiz Borrego, et al.
Journal of the National Cancer Institute|May 29, 2008
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancerMiguel Martín, Alvaro Rodríguez-Lescure, Amparo Ruiz, et al.
Pageof 18